AstraZeneca Loses IP Shield For Diabetes Drug
AstraZeneca has failed to convince a London judge to uphold supplementary patent protections for its billion-dollar diabetes drug dapagliflozin, in a ruling that helps clear a path for generic competition in...To view the full article, register now.
Already a subscriber? Click here to view full article